Multiple Myeloma Therapy Market is gaining importance as healthcare systems seek more effective ways to manage the growing burden of multiple myeloma. Continuous research and development activities are introducing therapies designed to address different stages and characteristics of the disease.

One of the key developments in this field is the increasing use of immune-based treatment strategies. Monoclonal antibodies and CAR-T cell therapies are receiving considerable attention because they offer approaches that differ from traditional chemotherapy. These innovations are contributing to a broader and more diversified treatment environment.

The market also covers therapies used during different phases of disease management. Initial treatment aims to establish disease control, while relapsed treatment addresses cases where the cancer returns or becomes resistant. Maintenance therapies can subsequently be used to help extend disease control.

According to WiseGuyReports, the global market is expected to grow from USD 39.8 billion in 2025 to approximately USD 75.0 billion by 2035. The report projects a CAGR of around 6.5% for the 2026–2035 period.

Future opportunities are expected to arise from innovative drug combinations, advances in personalized medicine, expanding immunotherapy adoption, and increased investment in emerging healthcare markets. However, differences in treatment accessibility, healthcare infrastructure, and affordability may continue to influence regional market development.